A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy.

INTRODUCTION Thrombotic thrombocytopenic purpura is a rare life-threatening disorder characterized by thrombocytopenia and microangiopathic hemolytic anemia. It is caused by the absent or severe deficiency of the von Willebrand Factor-cleaving protease named ADAMTS13. Pregnancy is a well recognized factor precipitating the appearance of the disease both in women that had reduced levels of ADAMTS13 activity prior to gestation and in those with other inherited or acquired thrombophilic syndromes. CASE REPORT We report a 25-year old woman with severe ADAMTS13 deficiency presented early in her 1st pregnancy and relapsed in two subsequent gestations. This presentation is uncommon for thrombotic thrombocytopenic purpura is associated with pregnancy (ADAMTS13 deficiency < 5%, without an inhibitor). In the first pregnancy she started with daily plasma exchange 1.5 x volume, corticosteroids and IV immunoglobulin and finally entered remission after 23 sessions and termination of pregnancy. In the second pregnancy she did not receive prophylactic treatment and relapsed in the 3rd trimester. Prophylactic treatment during the third pregnancy with plasma infusions proved also ineffective to prevent relapse. DISCUSSION Many issues regarding treatment and prevention of thrombotic thrombocytopenic purpura relapses in subsequent pregnancies are unclear. Proposed guidelines recommend that the same treatment should be performed on pregnant and non pregnant patients without modification of plasma replacement dose according to ADAMTS13 levels. In addition, many authors suggest that pregnant patients with history of thrombotic thrombocytopenic purpura and severe deficiency of ADAMTS13 levels should received prophylactic treatment for prevention of relapses in the subsequent pregnancies. CONCLUSION Severe ADAMTS 13 deficiency may present as thrombotic thrombocytopenic purpura of pregnancy. Pregnant women with thrombotic thrombocytopenic purpura and especially with severe deficiency of ADAMTS13 levels require specific consideration regarding treatment and prophylaxis in subsequent pregnancies.

[1]  S. Cataland,et al.  ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy , 2011, British journal of haematology.

[2]  M. Franchini.  Haemostasis and pregnancy , 2006, Thrombosis and Haemostasis.

[3]  Marie Scully,et al.  Successful management of pregnancy in women with a history of TTP. , 2006 .

[4]  S. Vesely,et al.  The incidence of thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS‐13 deficiency , 2005, Journal of thrombosis and haemostasis : JTH.

[5]  M. Lazzari,et al.  von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women , 2004, Thrombosis and Haemostasis.

[6]  S. Vesely,et al.  Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura–hemolytic uremic syndrome , 2004, Transfusion.

[7]  J. George.  The association of pregnancy with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome , 2003, Current opinion in hematology.

[8]  S. Vesely,et al.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. , 2003, Blood.

[9]  Kazuo Fujikawa,et al.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. , 2002, Blood.

[10]  P. Mannucci,et al.  Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. , 2001, Blood.

[11]  B. Lämmle,et al.  Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. , 2001, Best practice & research. Clinical haematology.

[12]  M. Esplin,et al.  Diagnosis and management of thrombotic microangiopathies during pregnancy. , 1999, Clinical obstetrics and gynecology.

[13]  B. Lämmle,et al.  Recovery and Half-Life of von Willebrand Factor-Cleaving Protease after Plasma Therapy in Patients with Thrombotic Thrombocytopenic Purpura , 1999, Thrombosis and Haemostasis.

[14]  D. Cines,et al.  Thrombotic microangiopathy during pregnancy. , 1997, Seminars in hematology.

[15]  B. Sibai,et al.  Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in pregnancy: review of 11 cases. , 1996, American journal of obstetrics and gynecology.

[16]  Y. Ezra,et al.  Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: A clinical study of 16 pregnancies , 1996, American journal of hematology.

[17]  C. Weiner.  Thrombotic microangiopathy in pregnancy and the postpartum period. , 1987, Seminars in hematology.

[18]  J. Pasquau Liaño,et al.  [Treatment of thrombotic thrombocytopenic purpura]. , 1987, Medicina clinica.

[19]  Dezra White.  Recurrent Thrombotic Thrombocytopenic Purpura in Early Pregnancy: Effect of Uterine Evacuation , 1985, Obstetrics and gynecology.

[20]  E. Moschcowitz.  Hyaline thrombosis of the terminal arterioles and capillaries : a hitherto undescribed disease , 1924 .